Advertisement
investing

Merck: A Great Dividend Stock for Retirees

The drug maker offers a healthy product pipeline including cancer-fighter Keytruda to go along with its healthy yield.

Dividends are the lifeblood of Big Pharma stocks. The payouts ensure a steady income stream even when a company’s shares stagnate. But a healthy dividend isn’t the only reason to consider the shares of Merck & Co. (symbol MRK). Not only does the drug maker’s stock deliver a 3.3% yield, it also has potential for gains.

Advertisement - Article continues below

With more than $39 billion in annual sales, Merck makes money from more than 50 prescription medicines. Top sellers include Januvia, a blockbuster diabetes drug, as well as drugs to treat cancer, high cholesterol and other ailments. Vaccines and animal health products round out Merck’s lineup.

Sales have dipped from a peak of $48 billion in 2011, partly because Merck sold its consumer-products business in 2014. Analysts expect profits per share to inch up by just 3.5% over the next 12 months (compared with earnings in the 12-month period that ended June 30). The stock has lagged far behind such rivals as Pfizer (PFE) and Bristol-Myers Squibb (BMY), trailing each by more than 20 percentage points over the past year.

But Merck could be on the cusp of breaking out of its rut. The Kenilworth, N.J., company recently spent $8.4 billion to acquire Cubist Pharmaceuticals, a leading maker of antibiotics, including drugs to treat “superbugs” that can cause pandemics. Merck says Cubist will add more than $1 billion to revenue in 2015 and bolster earnings per share in 2016. But more compelling from a profit perspective is Merck’s pipeline of new products, including several with potential for more than $1 billion in annual sales.

Merck's Next Blockbusters?

Leading the way is Merck’s cancer drug Keytruda, part of a new class of “immuno-oncology” medicines that harness the body’s defenses to shrink tumors. Already approved to treat melanoma, a form of skin cancer, Keytruda has shown effectiveness in treating some types of advanced lung cancer—a potentially much larger market. The Food and Drug Administration is slated to rule on Merck’s application for Keytruda to treat non-small-cell lung cancer in early October. Assuming Merck gets the green light and receives FDA approvals for other uses—two big ifs—Keytruda sales could reach $9 billion by 2023, estimates Bank of Montreal Capital Markets analyst Alex Arfaei.

Advertisement
Advertisement - Article continues below
Advertisement - Article continues below

Other potential hits include a new drug for hepatitis C; a weekly diabetes drug (potentially expanding Merck’s share of the diabetes-treatment market); and an anesthesia drug that has already been approved in Australia, Europe and Japan, and is under review by the FDA. All told, Merck is “on the verge of five to six years of strong growth,” says Arfaei, who recently upgraded the stock from a rating of “neutral” to “outperform” and raised his 12-month price target to $70 per share, 30% above Merck’s closing price on August 24 of $53.99.

Merck still faces tough competition. Keytruda and other drugs vie for sales against rivals, and pressure from insurance companies could force Merck to lower prices, reducing profitability. Moreover, although future products look exciting, some may never reach the market. And there’s always the chance that doctors will favor treatments made by other companies.

Yet investors aren’t paying a steep price for Merck’s future profit potential. The shares trade at 15 times estimated earnings of $3.60 per share over the next 12 months. That’s roughly in line with the price-earnings ratios of Pfizer and Johnson & Johnson (JNJ). But investors may be underestimating the value of Merck’s pipeline of new products, says Morningstar analyst Damien Connover. Even if the stock doesn’t bounce over the near term, investors can collect that healthy dividend yield as they wait for all those drugs to reach pharmacy shelves.

Advertisement

Most Popular

What Are the Income Tax Brackets for 2020 vs. 2019?
tax brackets

What Are the Income Tax Brackets for 2020 vs. 2019?

The IRS unveiled the 2020 tax brackets, and it's never too early to start planning to minimize your future tax bill.
June 20, 2020
Tax Changes and Key Amounts for the 2020 Tax Year
tax law

Tax Changes and Key Amounts for the 2020 Tax Year

Americans are facing a long list of tax changes for the 2020 tax year...and it's never too early to start thinking about next year's return.
June 22, 2020
10 Tax Breaks for the Middle Class
tax deductions

10 Tax Breaks for the Middle Class

Tax breaks aren't just for the rich. There are plenty of them that are only available to middle- and low-income Americans.
June 30, 2020

Recommended

13 Dividend Stocks That Have Paid Investors for 100+ Years
stocks

13 Dividend Stocks That Have Paid Investors for 100+ Years

Here are 13 dividend stocks that each boast a rich history of uninterrupted payouts to shareholders that stretch back at least a century.
May 21, 2020
20 Dividend Stocks to Fund 20 Years of Retirement
stocks

20 Dividend Stocks to Fund 20 Years of Retirement

These 20 high-quality dividend stocks yield roughly 4% or higher and should grow their payouts even more -- a powerful 1-2 combo for retirement income…
March 9, 2020
Closing Bell 7/8/20: Tech Stocks Lead Wall Street Forward Again
Markets

Closing Bell 7/8/20: Tech Stocks Lead Wall Street Forward Again

U.S coronavirus cases continue to spike, but Apple helped lead another Big Tech rally to drive the major indices higher Wednesday.
July 8, 2020
65 Best Dividend Stocks You Can Count On
stocks

65 Best Dividend Stocks You Can Count On

These 65 Dividend Aristocrats are an elite group of dividend stocks that have reliably increased their annual payouts every year for at least a quarte…
July 8, 2020